BioPortfolio Biotechnology Pharmaceutical Healthcare Medical Life Science Drug Discovery Disease

«Acneiform Eruptions

Below is an extended Acneiform Eruptions research listing. Click here to return to the Acneiform Eruptions main in depth entry.

Recent Publications on Acneiform Eruptions:

Aripiprazole-induced acneiform eruption.
Drug-induced acneiform eruptions are inflammatory follicular reactions...
Direct Link
9th September, 2008
Central Institute of Psychiatry, Kanke, Ranchi, Jharkhand 834006, India.
Erlotinib-induced florid acneiform rash complicated by extensive impetiginization.
Erlotinib (Tarceva) is an epidermal growth factor receptor (EGFR)...
Direct Link
30th July, 2008
Department of Dermatology, University Medical Centre Groningen, University
[Acneiform eruption secondary to cetuximab with pseudomalignant histopathological changes] 17th July, 2008
Depression and suicidal behavior in acne patients treated with isotretinoin: a systematic review.
Isotretinoin (13-cis retinoic acid) is an effective treatment for severe...
Direct Link
13th June, 2008
Department of Dermatology, University of California San Francisco, San
Cetuximab-induced acneiform eruption and the response to isotretinoin.
Sirolimus is an immunosuppressive macrolide with antineoplasic properties...
Direct Link
3rd June, 2008
[Acneiforme rash in woman with pulmonary adenocarcinoma] 7th May, 2008
Servicio de Oncologia, Hospital Clinico de Salamanca, Salamanca, Spain.
Acneiform eruption induced by cetuximab. 7th May, 2008
Department of Biomedical and Surgical Science, University of Verona,
Acneiform eruption following anti-TNF-alpha treatment: a report of three cases. 6th May, 2008
Department of Dermatology, Baylor College of Medicine, Houston, TX 77030,
Sirolimus-induced inflammatory papules with acquired reactive perforating collagenosis.
Sirolimus is an immunosuppressive macrolide with antineoplasic properties...
Direct Link
25th April, 2008
Clinique et Policlinique de Dermatologie et Venereologie, Hopital Cantonal
Side effects and complications of fractional laser photothermolysis: experience with 961 treatments.
BACKGROUND: A novel 1,550-nm erbium-doped laser (Fraxel, Reliant...
Direct Link
7th March, 2008
Washington Institute of Dermatologic Laser Surgery, Washington, DC 20005,
Uncovering Pandora's vase: the growing problem of new toxicities from novel anticancer agents. The case of sorafenib and sunitinib.
As newer, molecularly targeted, anticancer drugs are entering clinical...
Direct Link
6th February, 2008
Medical Oncology, IRCCS San Matteo University Hospital Foundation,
Acneiform reaction to erlotinib. 2nd February, 2008
Department of Dermatology, Harvard Medical School, Boston, MA, USA.
Side-effects of topical androgenic and anabolic substances and steroids. A short review. 23rd January, 2008
Department of Dermatology and Allergology, Academic Teaching Hospital
Randomized double-blind trial of prophylactic oral minocycline and topical tazarotene for cetuximab-associated acne-like eruption.
PURPOSE: To evaluate the ability of either oral minocycline, topical...
Direct Link
14th December, 2007
Dermatology Service and Gastrointestinal Oncology Service, Department of
[Adverse cutaneous drug reactions]
Cetuximab is a recombinant human/mouse chimeric monoclonal antibody that...
Direct Link
11th December, 2007
Klinik und Poliklinik fur Dermatologie und Allergologie der
 

Nothing in this website should be used in place of personal medical advice from your own qualified medical practitioner.  See User Agreement

Send comments and feedback to:
Peter Barfoot Managing Director, BioPortfolio Ltd.
UK Tel: (+44) 1300 321501
USA Voicemail and Fax: (+1) 415 680 2472

All rights reserved. All other trademarks recognized.

BioPortfolio Limited is registered in England & Wales at Wessex Barn, Dorchester Road, Frampton, Dorset, DT2 9NB, UK. No.3312883 VAT No. GB 744 6483 10

Copyright 1997-2008 - BioPortfolio Limited.

BioPortfolio logo

Valid XHTML 1.0 Transitional